Oliver Dorigo, MD, PhD

Oliver Dorigo, MD, PhD, is the Director of the Division of Gynecologic Oncology at Stanford. He received his medical degree from the University of Heidelberg Medical School in Germany. Following his MD degree, he underwent residency training in Obstetrics and Gynecology at the University of Munich, Germany. Dr. Dorigo then joined the Cancer Gene Therapy program at the Sidney Kimmel Cancer Center in San Diego, CA, and participated in early clinical trials using genetically modified tumor cell vaccines for the treatment of cancer. He subsequently completed his residency in Obstetrics and Gynecology at the UCLA David Geffen School of Medicine, Los Angeles, CA. He earned a PhD degree in Molecular Biology for his work on the development of a new gene transfer system that uses helper dependent adenovirus mediated delivery of an Epstein Barr Virus episome.

Dr. Dorigo completed a clinical fellowship in Gynecologic Oncology at UCLA/Cedars Sinai Medical Center, Los Angeles, CA. He was a faculty member in the UCLA Division of Gynecologic Oncology from 2005 to 2013. Dr. Dorigo was then appointed as the Director of the Stanford Gynecologic Oncology Service. At Stanford, he is directing the Clinical Research Group that is conducting clinical trials for gynecologic cancers that mainly involve immunotherapy. He is currently leading an international clinical trial that investigates the efficacy of a novel vaccine in recurrent, platinum-resistant ovarian cancer. Another trial is studying the clinical efficacy of an oncolytic virus delivered by cytokine induced killer cells in patients with ovarian and other cancers. Dr. Dorigo’s efforts are supported by the Stanford Cancer Institute and the Stanford Center for Cancer Cell Therapy. In addition, Dr. Dorigo directs the Gynecologic Oncology Clinical Care Program at the Stanford Women’s Cancer Center. His laboratory is focused on studying the role of macrophages in ovarian cancer.

Dr. Dorigo’s scientific work is published in various scientific journals, including Nature, Cell Development, Journal of Virology, Proceedings of the National Academy of Sciences, Journal of Immunology, Cancer Research, Communications Biology, and Cancer Gene Therapy.